AbCellera Biologics Inc (ABCL) concluded trading on Wednesday at a closing price of $2.42, with 4.05 million shares of worth about $9.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.60% during that period and on June 04, 2025 the price saw a gain of about 4.76%. Currently the company’s common shares owned by public are about 298.36M shares, out of which, 223.95M shares are available for trading.
Stock saw a price change of 18.63% in past 5 days and over the past one month there was a price change of 10.50%. Year-to-date (YTD), ABCL shares are showing a performance of -17.41% which decreased to -38.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.89 but also hit the highest price of $3.89 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 4.06 million. The stock is currently trading 17.11% above its 20-day simple moving average (SMA20), while that difference is up 8.51% for SMA50 and it goes to -8.72% lower than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 298.36M outstanding shares and institutions hold larger chunk of about 41.07% of that.
The stock has a current market capitalization of $722.33M and its 3Y-monthly beta is at 0.36. It has posted earnings per share of -$0.57 in the same period. It has Quick Ratio of 10.15 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 3.71% while standing at 2.92% over the month.
Analysts are in expectations that AbCellera Biologics Inc (ABCL) stock would likely to be making an EPS of -0.16 in the current quarter, while forecast for next quarter EPS is -0.16 and it is -0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.19 which is -0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.13 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -13.51% while it is estimated to increase by 7.95% in next year. EPS is likely to grow at an annualized rate of -2.32% for next 5-years, compared to annual growth of -107.74% made by the stock over the past 5-years.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
